Top Markets
Coin of the day
BioAge Labs Inc. BioAge Labs Inc.

BioAge Labs Inc.

BIOA
Rang in Aktien #15401
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Aktienkurs
$9.50
Marktkapitalisierung
$357.48M
Veränderung (1 Tag)
-0.05%
Veränderung (1 Jahr)
92.60%
Land
US
Handel BioAge Labs Inc. (BIOA)

Kategorie

Aktien-Split-Historie für BioAge Labs Inc. (BIOA)
Die Aktie BioAge Labs Inc. (Symbol: BIOA) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Sep 01, 2026 statt.
Eine BIOA-Aktie, die vor dem Sep 01, 2026 gekauft wurde, entspricht heute 0 BIOA-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH